An Open and Dose-escalation Early Clinical Study of CD19 and CD20 CAR-T Cell Therapy for Relapsed or Refractory Aggressive B-cell Lymphoma

To observe the efficacy and safety of dual-target chimeric antigen receptor T cells in the treatment of refractory or relapsed aggressive B-cell lymphoma

Trial Details

NCT ID
NCT07344818
Phase
EARLY_PHASE1
Sponsor
Peking University People's Hospital
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • CAR-T cell therapy
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • The subject or his/her legal guardian is able to understand and voluntarily sign the informed consent form (ICF).
  • Male or female subjects aged ≥18 years at the time of signing the ICF.
  • An expected life expectancy of at least 12 weeks.
  • An ECOG performance status of 0-2 at the time of signing the ICF.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →